Hang Quach (H Quach)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 20

Top Topics

Multiple Myeloma

Newly Diagnosed

Prognostic Factors

Top Venues

British journal of haematology

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon Gibbs, Sophie Lee, Edwin Lee, Kerry Taylor, Tara Cochrane, Craig Wallington-Gates, Fiona Kwok, Nicholas Weber, Ian Kerridge, Helen Weston, P Joy Ho, Michael Francis Leahy, Noemi Horvath, Andrew Spencer
Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16). Blood advances (2024)
Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon Gibbs, Sophie Lee, Edwin Lee, Kerry Taylor, Tara Cochrane, Craig Wallington-Gates, Fiona Kwok, Nicholas Weber, Ian Kerridge, Helen Weston, P Joy Ho, Michael Francis Leahy, Noemi Horvath, Andrew Spencer
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16. Blood advances 8 (14) (2024)
P Joy Ho, Elizabeth M Moore, Cameron Wellard, Hang Quach, Hilary Blacklock, Simon James Harrison, Emma-Jane MacDonald, Zoe K McQuilten, Erica M Wood, Peter Mollee, Andrew Spencer
The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR). British journal of haematology (2024)
Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon Gibbs, Sophie Lee, Edwin Lee, Kerry Taylor, Tara Cochrane, Craig Wallington-Gates, Fiona Kwok, Nicholas Weber, Ian Kerridge, Helen Weston, P Joy Ho, Michael Francis Leahy, Noemi Horvath, Andrew Spencer
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16. Blood advances 8 (14) (2024)
Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Simon Gibbs, Sophie Lee, Edwin Lee, Kerry Taylor, Tara Cochrane, Craig Wallington-Gates, Fiona Kwok, Nicholas Weber, Ian Kerridge, Helen Weston, P Joy Ho, Michael Francis Leahy, Noemi Horvath, Andrew Spencer
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16. Blood advances 8 (14) (2024)
Sueh-Li Lim, J Reynolds, Hang Quach, A Hutchinson, Ian Kerridge, W Janowski, K Bergin, Andrew Spencer
Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21. British journal of haematology (2024)
Andrew Spencer, Anna Kalff, Jake Shortt, Hang Quach, Craig Wallington-Gates, John Reynolds, Patricia Walker, Simon James Harrison, Rosanne Dunn, Cameron Wellard
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16). British journal of haematology (2023)
R Turner, Hang Quach, N Horvath, I Kerridge, E Lee, E Morris, Anna Kalff, T Khong, J Reynolds, Andrew Spencer
Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial. British journal of haematology (2023)
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos-Manteca, Carl Ola Landgren, Xavier Leleu, David S Siegel, Katja C Weisel, Xiaomei Shu, Chuang Li, Meletios A Dimopoulos
Final Analysis of Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in the CANDOR Study. Blood advances (2023)
Paul G Richardson, Maria-Victoria Mateos-Manteca, Annette J Vangsted, Karthik Ramasamy, Niels Abildgaard, P Joy Ho, Hang Quach, Nizar J Bahlis
The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease. Expert review of proteomics (2022)
Gareth Peter Gregory, Shaji K Kumar, Ding Wang, Daruka Mahadevan, Patricia Walker, Nina D Wagner-Johnston, Carolina Escobar, Rajat Bannerji, Divaya Bhutani, Julie Chang, Francisco J Hernandez-Ilizaliturri, Andreas Klein, John M Pagel, Witold B Rybka, Andrew J Yee, Anne Mohrbacher, Mo Huang, Mohammed Farooqui, Patricia Marinello, Hang Quach
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood advances 6 (4) (2022)
Thomas Martin, Joseph R Mikhael, Roman Hájek, Kihyun Kim, Kenshi Suzuki, Cyrille Hulin, Mamta Garg, Hang Quach, Hanlon Sia, Anup George, Tatyana S Konstantinova, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Helgi van de Velde, Philippe Moreau
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood advances 6 (15) (2022)
Joanne L C Tan, Cameron Wellard, Elizabeth M Moore, Peter Mollee, Rajeev Rajagopal, Hang Quach, Simon James Harrison, Emma-Jane McDonald, P Joy Ho, Henry Miles Prince, Bradley M Augustson, Philip Campbell, Zoe K McQuilten, Erica M Wood, Andrew Spencer, null null
The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population. British journal of haematology (2022)
Zoe K McQuilten, Cameron Wellard, Elizabeth M Moore, Bradley Augustson, Krystal Bergin, Hilary Blacklock, Simon James Harrison, P Joy Ho, Tracy King, Hang Quach, Peter Mollee, Brian Rosengarten, Patricia Walker, Erica Wood, Andrew Spencer, null null
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). British journal of haematology 198 (5) (2022)
Hang Quach
MRD end point in myeloma: ready for prime time? Blood 139 (6) (2022)
Jesús San F Miguel, Hervé Avet-Loiseau, Juan José Lahuerta, Shaji K Kumar, Meletios A A Dimopoulos, Thierry Facon, Maria-Victoria Mateos-Manteca, Cyrille Touzeau, Andrzej J Jakubowiak, Saad Z Usmani, Gordon Cook, Michele Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J Bahlis
Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE. Blood (2021)
Nizar J Bahlis, Rachid Baz, Simon J Harrison, Hang Quach, Shir Jing Ho, Annette Juul Vangsted, Torben Plesner, Phillipe Moreau, Simon D Gibbs, Sheryl Coppola, Xiaoqing Yang, Abdullah Al Masud, Jeremy A Ross, Orlando Bueno, Jonathan L Kaufman
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (32) (2021)
Hang Quach, Ajay Nooka, Olga Samoylova, Christopher P Venner, Kihyun Kim, Thierry Facon, Andrew Spencer, Saad Z Usmani, Sebastian Grosicki, Kenshi Suzuki, Sosana Delimpasi, Katja Weisel, Mihaela Obreja, Anita Zahlten-Kumeli, Maria-Victoria Mateos-Manteca
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. British journal of haematology 194 (4) (2021)
Maciej Tatarczuch, Erin Paul, Michael Gilbertson, Gareth Peter Gregory, Constantine S Tam, Hang Quach, Ali Bazargan, Robin Filshie, Matthew Ku, Amanda Tey, Jake Shortt, Stephen Samuel Opat
Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. Leukemia & lymphoma 62 (1) (2020)
Mansi Bhurani, Lorenz Admojo, Carrie Van Der Weyden, Robert Twigger, Ali Bazargan, Hang Quach, Allan Zimet, Luke Coyle, Julian Lindsay, Dejan Radeski, Eliza Hawkes, Glen Kennedy, Ian Irving, Naadir Gutta, Judith Trotman, James Yeung, Lindsay Dunlop, Minh Hua, Pratyush Giri, Sam Yuen, Shyam Panicker, Susan Moreton, Liane Khoo, Ashleigh Scott, David Kipp, Andrew McQuillan, Chris McCormack, Michael Dickinson, Henry Miles Prince
Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. Leukemia & lymphoma 62 (2) (2020)